Last Posted: Dec 05, 2019
- A four-gene expression-based signature predicts the clinical outcome of melanoma.
Sun Liping et al. Journal of B.U.ON. : official journal of the Balkan Union of Oncology 24(5) 2161-2167 - Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma
D Liu et al, Nature Medicine, December 2, 2019 - Precision Medicine in the Treatment of Melanoma.
Aderhold Kimberly et al. Surgical oncology clinics of North America 2020 Jan 29(1) 1-13 - Role of Heredity in Melanoma Susceptibility: A Primer for the Practicing Surgeon.
Abdo James F et al. The Surgical clinics of North America 2020 Feb 100(1) 13-28 - The androgen receptor expression and association with patient's survival in different cancers.
Hu Chao et al. Genomics 2019 Nov - Genetic Biomarkers For Hepatocellular Carcinoma In The Era Of Precision Medicine.
Duan Jingxian et al. Journal of hepatocellular carcinoma 2019 6151-166 - CRISPR Approach To Fighting Cancer Called 'Promising' In 1st Safety Test
R Stein, NPR, November 6, 2019 - Superpixel-Based Conditional Random Fields (SuperCRF): Incorporating Global and Local Context for Enhanced Deep Learning in Melanoma Histopathology.
Zormpas-Petridis Konstantinos et al. Frontiers in oncology 2019 91045 - CMS Aims to Broaden Coverage for NGS Testing in Breast, Ovarian Cancer -Expansion would include patients with risk factors for inherited susceptibility mutations
I Ingram, MedPage Today, October 31, 2019 - A whole-blood RNA transcript-based gene signature is associated with the development of CTLA-4 blockade-related diarrhea in patients with advanced melanoma treated with the checkpoint inhibitor tremelimumab.
Friedlander Philip et al. Journal for immunotherapy of cancer 2018 6(1) 90
.png)
No hay comentarios:
Publicar un comentario